Editorial

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with $^{177}$Lu-PSMA radioligand therapy

Finn Edler von Eyben$^1$, Harshad R. Kulkarni$^2$, Richard P. Baum$^2$

1. Center of Tobacco Control Research, Odense, Denmark;
2. Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.

Corresponding author: Finn Edler von Eyben, M.D., Ph. D. Email finn113edler@mail.tele.dk.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2020.02.04; Accepted: 2020.02.12; Published: 2020.03.30

Abstract

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment.

Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with $^{177}$Lu PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.

Key words: prostate specific membrane antigen, $^{177}$Lutetium [$^{177}$Lu]-PSMA radioligand therapy, prostatic neoplasms, restaging, overall survival

The publication by Kessel et al. on $^{177}$Lu prostate specific membrane antigen (PSMA) radioligand therapy (PRLT) for patients with metastatic multidrug-resistant and castration-resistant prostate cancer (mCRPC) is interesting [1]. Previous publications found visceral metastases had negative impact on overall survival (OS) after PRLT [2-5], whereas the Kessel publication evaluated whether PRLT for patients with bone, lung, and liver metastases differed in OS. The authors found that patients with or without lung metastases did not differ in OS.

In contrast, patients with liver metastases had a worse OS than patients without liver metastases. The findings pointed to a heterogeneity between patients with lung and liver metastases. In multivariate analyses, visceral metastases, both lung and liver metastases, had a significant negative impact on OS.

As an external validation of the findings, another German center, the Zentralklinik Bad Berka (ZBB), evaluated 174 consecutive patients. The OS is shown in Figure 1. Twenty-eight patients had lymph node metastases (LNM) with or without one or two bone metastases (site 1 and 2 in the figure), 102 had multiple bone metastases (site 3), 21 had lung metastases (site 4), and 23 had liver metastases (site 5). Treatment with $^{177}$LuPRTL included median 3 cycles, median 6.3 GBq per cycle, and median 8 weeks intervals between the cycles [6].

Of the patients, those with bone and lung metastases had grossly similar OS whereas the patients with liver metastases had a worse OS. In addition, patients with only LNM with or without one or two bone lesions had the best OS. The five patient groups differed markedly in OS (p < 0.0001, log rank test). The findings confirmed those of Kessel et al.. The groups of patients treated at ZBB had a trend for OS that corroborated with that for the groups of patient...
Kessel et al. reported.

ZBB first reported that patients with LNM had a favorable outcome after PRLT in 2016 [7]. A recent paper of 45 patients with LNM confirmed that PRLT resulted in an impressive long OS for these patients [8]. Also a systematic review of nine trials of patients with mCRPC treated with docetaxel found that patients with LNM had a better OS than those with bone, lung, and liver metastases [9]. The review summarized more than 8000 patients. Patients with liver metastases treated with docetaxel had the worst OS.

Since nine trials of docetaxel as first-line treatment of mCRPC and two separate studies of PRLT as last-line treatment show the same trend for OS, it can be concluded that the sites of the progressing metastases of mCRPC differ in tumor biology. Kessel et al. discussed further that genetic changes in the progression of the metastases may contribute to the reduced outcome after treatment of the most advanced metastases. This idea is indeed thought-provoking.

Evaluated patients with bone, lung, and liver metastases had similar OS whether the patients had been treated with first-line docetaxel or last-line 177 LuPRLT. Therefore, we extrapolated that patients with LNM would have had a similar OS whether treated with docetaxel or PRLT. But, interestingly for patients with LNM, PRLT resulted in a better OS than docetaxel. The discrepancy suggests that for these patients PRLT has a significant effect on OS which cannot be ascribed only to a lead time phenomenon.

Guidelines from the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) on reporting of trials of mCRPC laid emphasis on restaging with conventional imaging modalities such as CT and bone scans [10]. But PSMA PET/CT is more sensitive and is increasingly used worldwide in the daily routine [11, 12]. For patients with multiresistant mCRPC, a positive PSMA PET/CT is mandatory for initiation of PRLT. But today most patients with progressive prostate cancer and a positive PSMA PET/CT are not treated with PRLT.

Another recent analysis showed that also asymptomatic patients with mCRPC treated with PRLT had a two-year OS of 100%, clearly above the median OS of 13 months generally observed for PRLT of patients with multi-resistant mCRPC [13]. Thus findings of retrospective studies such as that by Kessel et al. help to design new prospective controlled randomized trials to maximize the effect as patients with prostate cancer are treated with PRLT.

**Abbreviations**

LNM: lymph node metastases; mCRPC: metastatic castration-resistant prostate cancer; OS: overall survival; PRLT: PSMA radioligand therapy; PSMA: prostate specific membrane antigen; PCWG3: Prostate Cancer Clinical Trials Working Group 3.

![Figure 1](http://www.thno.org)
Competing Interests

The authors have declared that no competing interest exists.

References


